Tonix Pharmaceuticals stock halted ahead of FDA approval news
On Wednesday, Nuvama Research initiated coverage on BSE Limited (BSE:IN), the oldest stock exchange in Asia, with a Buy rating and a price target set at INR 6,730.00. The firm underscored BSE's adaptability and potential for growth despite recent regulatory changes affecting index derivatives.
The analyst from Nuvama highlighted that while the discontinuation of weekly contracts might impact 21.3% of BSE's average daily premium turnover volume (ADPTV), there is a significant opportunity to expand the exchange's customer base, which currently stands between 1.5 to 2 million users. Nuvama also pointed out that increased contract sizes could lead to lower clearing charges, positively affecting BSE's EBITDA margin.
Looking at the longer-term prospects, the research firm emphasized BSE's diversified revenue streams, including StAR MF, AIPL, and colocation services, which are expected to contribute to the exchange's growth. Nuvama has forecasted a robust compound annual growth rate (CAGR) for BSE's revenue and after-tax profit (APAT) of 39.9% and 70.8%, respectively, from FY24 to FY27E. This growth is projected to boost BSE's return on equity (RoE) to 37.9%.
The Buy rating and price target are based on a FY27E price-to-earnings (PE) ratio of 50x, which Nuvama justifies by referring to the industry's duopolistic nature. Additionally, the valuation includes the worth of BSE's stake in Central Depository Services Limited (CDSL). Despite the challenges posed by the regulatory changes, Nuvama remains confident in BSE's ability to adapt and capitalize on its growth potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.